Extended Data Fig. 3: Change from baseline for MDS-UPDRS Part I of PASADENA (early- and delayed-start) against PPMI. | Nature Medicine

Extended Data Fig. 3: Change from baseline for MDS-UPDRS Part I of PASADENA (early- and delayed-start) against PPMI.

From: Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial

Extended Data Fig. 3

Error bars represent 80% CI. CI, confidence interval; MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; PASADENA, Phase II trial of Anti alpha-Synuclein AntiboDy in Early ParkiNson's diseAse; PPMI, Parkinson’s Progression Markers Initiative.

Back to article page